Anavex Life Sciences Corp (AVXL)

[hnbadger1]

Dr. Daniel Klamer (VP, Business Development & Scientific Strategy / longtime, key member of the management team at Anavex) will be presenting at the 15th Annual Outsourcing in Clinical Trials East Coast 2024 conference on May 21st:
CASE STUDY: TARGETING ALZHEIMER'S DISEASE AND DEMENTIA IN PARKINSON'S DISEASE WITH BLARCAMESINE (ANAVEX®2-73)
Clinical efficacy is associated with biomarker expression and restoration of neurodegenerative pathways
• Blarcamesine (ANAVEX®2-73) treatment result in significant improvements in patients with Alzheimer's Disease and in Parkinson's
Disease Dementia
• Analysis demonstrates predictive biomarker of efficacy in Alzheimer's Disease and in Parkinson's Disease Dementia
• Whole blood transcriptomics analysis (RNAseq) identifies treatment impact on pathways impaired in neurodegenerative diseases
https://www.arena-international.com/event/
octeastcoast/#agenda
Outsourcing in Clinical Tri
OCT East coast
arena-international.com
THANKS Michael Tavares from the FB group!